Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CDX1307 · 2 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| CDX-1307 | BIOLOGICAL | - |
| CDX1307 | BIOLOGICAL | - |
Inclusion Criteria 1. Patients must have incurable, metastatic or unresectable locally advanced breast, colorectal, pancreatic, bladder or ovarian cancer with measurable or evaluable-only disease. Locally advanced breast cancer is defined as inflammatory breast cancer with biopsy-proven skin involv...
Top 20 of 92 competitors
CDX1307 is an investigational monoclonal antibody being studied for the treatment of breast cancer, as well as colorectal, pancreatic, bladder, and ovarian cancers. It is being developed by Celldex Therapeutics, Inc. (CLDX) and is currently in Phase 1 clinical development.
CDX1307 is being developed by Celldex Therapeutics, Inc., a biopharmaceutical company traded under the ticker symbol CLDX. The drug is an investigational monoclonal antibody in Phase 1 clinical development for the treatment of breast cancer and other solid tumors.
CDX1307 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. Two Phase 1 trials have been completed, with a total enrollment of 84 patients.
CDX1307 has been studied in two completed Phase 1 clinical trials: NCT00648102, which enrolled 36 patients, and NCT00709462, which enrolled 48 patients. Both trials included patients with breast, colorectal, pancreatic, bladder, or ovarian cancer and were conducted in the United States.
CDX1307 is described as a monoclonal antibody, but one of its clinical trials, NCT00648102, refers to it as a 'hCG-B Vaccine.' This suggests the drug may have vaccine-like properties, though it is classified as a monoclonal antibody in development for cancer treatment.